|
|
| As of 20th May 2009, the novel triple reassortant H1N1 influenza A, virus previously referred to as "swine flu" has caused over 10,000 laboratory confirmed cases of infection with 80 deaths. 41 countries have reported infection with over half of the cases being identified in the continental United States.
Using currently available information regarding the expected profile, possible allocation of H1N1 specific vaccine and predictions of pandemic severity, VacZine Analytics has modelled a potential vaccine demand scenario in the United States. The provided model and presentation also give indications of potential cumulative revenue (for vaccine manufacturers) and required antigen amounts (approximation) for a full vaccination campaign. |
Related Markets
Pandemic Vaccines Reports
- Research Report on Chinese Bio-pharmaceutical Industry, 2012
- Vaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts)
- Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast
- Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity
- Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
